CO6331436A2 - Oxazolopirimidinas como agonistas del receptor edg-1 - Google Patents
Oxazolopirimidinas como agonistas del receptor edg-1Info
- Publication number
- CO6331436A2 CO6331436A2 CO11003596A CO11003596A CO6331436A2 CO 6331436 A2 CO6331436 A2 CO 6331436A2 CO 11003596 A CO11003596 A CO 11003596A CO 11003596 A CO11003596 A CO 11003596A CO 6331436 A2 CO6331436 A2 CO 6331436A2
- Authority
- CO
- Colombia
- Prior art keywords
- formula
- compounds
- edg
- agonists
- receptor
- Prior art date
Links
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 title abstract 2
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- BRIOKNPDCPJCOD-UHFFFAOYSA-N [1,3]oxazolo[5,4-d]pyrimidine Chemical class N1=CN=C2OC=NC2=C1 BRIOKNPDCPJCOD-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290694 | 2008-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6331436A2 true CO6331436A2 (es) | 2011-10-20 |
Family
ID=39967817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11003596A CO6331436A2 (es) | 2008-07-15 | 2011-01-14 | Oxazolopirimidinas como agonistas del receptor edg-1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8735387B2 (https=) |
| EP (2) | EP2583720A1 (https=) |
| JP (1) | JP5449346B2 (https=) |
| KR (1) | KR20110042286A (https=) |
| CN (1) | CN102159582B (https=) |
| AR (1) | AR072496A1 (https=) |
| AU (1) | AU2009270511B2 (https=) |
| BR (1) | BRPI0915781A2 (https=) |
| CA (1) | CA2730843A1 (https=) |
| CL (1) | CL2011000071A1 (https=) |
| CO (1) | CO6331436A2 (https=) |
| IL (1) | IL210639A0 (https=) |
| MA (1) | MA32455B1 (https=) |
| MX (1) | MX2011000211A (https=) |
| NZ (1) | NZ590377A (https=) |
| RU (1) | RU2503680C2 (https=) |
| TW (1) | TW201016707A (https=) |
| UY (1) | UY31981A (https=) |
| WO (1) | WO2010006704A1 (https=) |
| ZA (1) | ZA201008786B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI485153B (zh) | 2010-01-13 | 2015-05-21 | Sanofi Aventis | ２，５，７－經取代唑并嘧啶衍生物 |
| TWI478929B (zh) | 2010-01-13 | 2015-04-01 | Sanofi Aventis | 含２，５，７－經取代唑并嘧啶環之羧酸衍生物 |
| MX2012007837A (es) | 2010-01-14 | 2012-07-30 | Sanofi Sa | Derivados de oxazolopirimidina 2, 5 - sustituidos. |
| JP5841068B2 (ja) * | 2010-01-14 | 2016-01-06 | サノフイ | ２，５−置換されたオキサゾロピリミジン環を有する複素環式カルボン酸誘導体 |
| PT2523962E (pt) * | 2010-01-14 | 2014-02-06 | Sanofi Sa | Derivados de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5 |
| AU2011225122B8 (en) | 2010-03-12 | 2013-12-12 | Nippon Soda Co., Ltd. | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative |
| US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
| US8907093B2 (en) * | 2011-07-07 | 2014-12-09 | Sanofi | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| US9321787B2 (en) * | 2011-07-07 | 2016-04-26 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring |
| US8735402B2 (en) * | 2011-07-07 | 2014-05-27 | Sanofi | Cycloalkyloxycarboxylic acid derivatives |
| SI2841437T1 (sl) | 2012-04-26 | 2017-09-29 | Bristol-Myers Squibb Company | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
| SG11201406759YA (en) * | 2012-04-26 | 2014-11-27 | Bristol Myers Squibb Co | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| US10577308B2 (en) | 2015-03-26 | 2020-03-03 | The Florey Institute | Sodium channel modulators |
| WO2022224267A1 (en) * | 2021-04-21 | 2022-10-27 | Natco Pharma Limited | Improved process for the preparation of 7-(morpholinyl)-2-(n-piperazinyl)methylthieno[2, 3-c]pyridine derivatives |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3679682A (en) * | 1970-04-23 | 1972-07-25 | Fmc Corp | CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES |
| DK1390371T3 (da) * | 2001-05-14 | 2006-06-19 | Novartis Ag | Oxazolo- og furopyrimidiner samt deres anvendelse i lægemidler mod tumorer |
| WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| JP2006524672A (ja) | 2003-04-25 | 2006-11-02 | ユニバーシティー・カッレッジ・カーディフ・コンサルタンツ・リミテッド | ウイルス感染の治療において使用するための複素環式化合物 |
| MXPA05011597A (es) * | 2003-04-30 | 2005-12-15 | Novartis Ag | Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina. |
| CL2004001120A1 (es) * | 2003-05-19 | 2005-04-15 | Irm Llc | Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer. |
| AU2004272437A1 (en) | 2003-09-09 | 2005-03-24 | Ono Pharmaceutical Co., Ltd. | CRF antagonists and heterobicyclic compounds |
| EP1697333A4 (en) | 2003-12-17 | 2009-07-08 | Merck & Co Inc | (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR |
| US20050239806A1 (en) | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| CA2583681A1 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| EP1965807A4 (en) * | 2005-11-23 | 2010-10-27 | Epix Delaware Inc | S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE |
| EP1900729A1 (en) * | 2006-09-15 | 2008-03-19 | Novartis AG | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
-
2009
- 2009-07-02 MX MX2011000211A patent/MX2011000211A/es active IP Right Grant
- 2009-07-02 CN CN200980135883.4A patent/CN102159582B/zh not_active Expired - Fee Related
- 2009-07-02 JP JP2011517773A patent/JP5449346B2/ja not_active Expired - Fee Related
- 2009-07-02 KR KR1020117001113A patent/KR20110042286A/ko not_active Withdrawn
- 2009-07-02 CA CA2730843A patent/CA2730843A1/en not_active Abandoned
- 2009-07-02 EP EP13151034.9A patent/EP2583720A1/en not_active Withdrawn
- 2009-07-02 AU AU2009270511A patent/AU2009270511B2/en not_active Ceased
- 2009-07-02 NZ NZ590377A patent/NZ590377A/en not_active IP Right Cessation
- 2009-07-02 BR BRPI0915781A patent/BRPI0915781A2/pt not_active IP Right Cessation
- 2009-07-02 RU RU2011105388/04A patent/RU2503680C2/ru not_active IP Right Cessation
- 2009-07-02 US US13/003,125 patent/US8735387B2/en not_active Expired - Fee Related
- 2009-07-02 WO PCT/EP2009/004770 patent/WO2010006704A1/en not_active Ceased
- 2009-07-02 EP EP09776914A patent/EP2318415B1/en active Active
- 2009-07-13 UY UY0001031981A patent/UY31981A/es not_active Application Discontinuation
- 2009-07-13 AR ARP090102624A patent/AR072496A1/es not_active Application Discontinuation
- 2009-07-13 TW TW098123561A patent/TW201016707A/zh unknown
-
2010
- 2010-12-07 ZA ZA2010/08786A patent/ZA201008786B/en unknown
-
2011
- 2011-01-05 MA MA33493A patent/MA32455B1/fr unknown
- 2011-01-12 CL CL2011000071A patent/CL2011000071A1/es unknown
- 2011-01-13 IL IL210639A patent/IL210639A0/en unknown
- 2011-01-14 CO CO11003596A patent/CO6331436A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201008786B (en) | 2012-01-25 |
| US20110190490A1 (en) | 2011-08-04 |
| EP2318415B1 (en) | 2013-02-20 |
| TW201016707A (en) | 2010-05-01 |
| CA2730843A1 (en) | 2010-01-21 |
| KR20110042286A (ko) | 2011-04-26 |
| MX2011000211A (es) | 2011-03-03 |
| CN102159582B (zh) | 2014-05-07 |
| EP2318415A1 (en) | 2011-05-11 |
| CN102159582A (zh) | 2011-08-17 |
| AU2009270511A1 (en) | 2010-01-21 |
| AR072496A1 (es) | 2010-09-01 |
| AU2009270511B2 (en) | 2013-07-18 |
| NZ590377A (en) | 2011-11-25 |
| JP2011527994A (ja) | 2011-11-10 |
| WO2010006704A1 (en) | 2010-01-21 |
| BRPI0915781A2 (pt) | 2015-11-10 |
| JP5449346B2 (ja) | 2014-03-19 |
| RU2503680C2 (ru) | 2014-01-10 |
| MA32455B1 (fr) | 2011-07-03 |
| UY31981A (es) | 2010-02-26 |
| RU2011105388A (ru) | 2012-08-20 |
| IL210639A0 (en) | 2011-03-31 |
| EP2583720A1 (en) | 2013-04-24 |
| US8735387B2 (en) | 2014-05-27 |
| CL2011000071A1 (es) | 2011-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6331436A2 (es) | Oxazolopirimidinas como agonistas del receptor edg-1 | |
| BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
| ECSP10010615A (es) | Derivados de benzofurano, benzotiofeno, benzotiazol como moduladores de fxr | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| CR20130432A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| UY33483A (es) | Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento. | |
| PY2084899A (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| EA201990851A1 (ru) | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 | |
| ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| UY33485A (es) | Derivados de acido(2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos. | |
| CL2008000806A1 (es) | Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras. | |
| TN2018000043A1 (en) | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors | |
| ECSP12011961A (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de | |
| DOP2010000324A (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino utiles como inhibidores del receptor del gen de diferenciacion endotelial 2 (edg-2) y su uso como productos farmaceuticos | |
| CO6470821A2 (es) | Pirazinilpirazoles | |
| CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
| DOP2013000130A (es) | Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2 | |
| CO6382119A2 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| UY32502A (es) | Agentes antihelmínticos y su utilización | |
| SV2012004235A (es) | Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR081774A1 (es) | Composiciones farmaceuticas de co-cristales de tramadol y coxibs | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| CL2011002103A1 (es) | Compuestos derivados de indazol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica y combinacion que los comprende; y uso para tratar una afeccion para la que esta indicado un antagonista del receptor ccr4. | |
| ECSP13012600A (es) | CO-cristales y Sales de Inhibidores de CCR3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |